# A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

> **NCT06825858** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Chengdu Origen Biotechnology Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** KH658

## Key facts

- **NCT ID:** NCT06825858
- **Lead sponsor:** Chengdu Origen Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2027-01
- **Final completion:** 2027-03
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06825858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06825858, "A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06825858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*